Is Ozempic used for drug addiction?
In recent years, medications like Ozempic and Wegovy have made headlines for their effectiveness in treating type 2 diabetes and facilitating dramatic weight loss. These drugs, part of a class called GLP-1 receptor agonists, have gained popularity not only among individuals managing diabetes but also among those seeking to reduce appetite and shed pounds. But as researchers dig deeper into how these drugs work in the body and brain, a new question is emerging: Could GLP-1 medication for opioid use become a real possibility?
New research suggests that GLP-1 receptor agonists may do more than suppress hunger—they may also reduce cravings, affect reward pathways, and play a role in substance use treatment. This blog by MAT Care Clinics explores the potential of GLP-1 for addiction treatment, especially in relation to opioid use disorder (OUD), and how it might someday work alongside traditional treatments like medication-assisted treatment (MAT).
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are medications that mimic a natural hormone in the body called glucagon-like peptide-1 (GLP-1). This hormone helps regulate blood sugar by increasing insulin secretion, decreasing glucagon levels, and slowing gastric emptying. These effects are beneficial in managing type 2 diabetes. Additionally, GLP-1 receptor agonists reduce appetite and promote a feeling of fullness, making them a popular treatment option for obesity.
Ozempic (semaglutide) and Wegovy are two of the most well-known GLP-1 drugs, which can also reduce body weight and improve metabolic health. However, researchers have begun to realize that these medications also act on the brain, specifically the regions tied to impulse control, craving, and reward.
How GLP-1 Medication Affects Addiction Pathways
The science connecting GLP-1 receptor agonists to addiction treatment lies in their ability to influence the brain’s reward system. This system, mainly driven by dopamine, plays a key role in both natural behaviors (eating, socializing) and addictive behaviors (drug use, gambling).
-
Impact on the Reward System
When a person consumes an addictive substance like opioids, their brain receives a surge in dopamine, creating feelings of pleasure and reinforcing the behavior. Over time, the brain craves more of the substance to achieve the same pleasure, leading to dependence.
GLP-1 receptor agonists reduce this dopamine response. Pharmacological research suggests these medications dampen the brain’s “reward signals,” making drug use less pleasurable by influencing brain systems involved in reward, stress, and self-control. For individuals with opioid addiction, this could mean fewer cravings and a reduced likelihood of relapse.
-
Regulating Cravings
GLP-1 medications are already proven to reduce cravings in people with food addiction. For example, individuals taking Ozempic often report a diminished interest in high-calorie foods like sweets and fried snacks. Similarly, early trials indicate these medications may weaken cravings for addictive substances, including opioids, alcohol, and nicotine.
In a small clinical trial led by Dr. Scott Bunce at Penn State College of Medicine, researchers tested whether GLP-1 medications—like those used for diabetes and weight loss—could help reduce opioid cravings. The study included 20 people in rehab for opioid use disorder (OUD); some were also taking the standard OUD medication buprenorphine.
Participants were randomly given either a GLP-1 medication or a placebo for 18 days and were asked multiple times a day to report their cravings. After three weeks, the group taking the GLP-1 experienced a 40% drop in cravings compared to those receiving standard treatment alone. Notably, even those not taking buprenorphine felt reduced cravings early on with the GLP-1 drug, suggesting it could be a promising new tool in treating OUD.
-
Stabilizing Dopamine Pathways
Beyond suppressing the effects of addictive substances, GLP-1 receptor agonists may also help stabilize dopamine levels, which contributes to behavioral changes, according to Frontiers. This regulation reduces the impulsive behaviors linked to substance-seeking. Over time, this could help break the cycle of addiction by addressing one of its root causes.
A Note of Caution Before Considering GLP-1 Medications
It’s important to emphasize that using GLP-1 medication for substance use is experimental. If you or someone you know is exploring alternatives to manage opioid addiction, consult a healthcare professional. They can guide you in a way that is tailored to your individual needs and ensures safe, effective care.
At MAT Care Clinics, we prioritize evidence-based approaches to addiction treatment. While we’re excited about the future of GLP-1 medications, we’re committed to using only proven, FDA-approved therapies to help individuals achieve long-term recovery.
MAT: The Current Gold Standard
MAT remains one of the most effective, evidence-based approaches for treating opioid addiction. It combines FDA-approved medications (such as Suboxone, Subutex, Vivitrol, and Sublocade) with counseling and behavioral therapies. MAT helps stabilize brain chemistry, reduce withdrawal symptoms, and lower the risk of relapse.
MAT Care Clinics: Proven Support, Grounded in Science
At MAT Care Clinics, our priority is your recovery. We specialize in evidence-based, FDA-approved MAT for opioid and alcohol use disorders. Our approach is rooted in the latest scientific advancements using FDA-approved medications.
We walk alongside you on your recovery journey. By combining medical integrity, clinical expertise, and personalized care, we aim to empower individuals to achieve lasting rehabilitation.
If you’re ready to take the next step or curious about how MAT can help, our compassionate team is here to guide you. Call us today at (833) 622-0628 or schedule a free consultation here. You don’t have to face this alone; we’re here to help.
